Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.

Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.

Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed. The glycogen manager formula includes the effective ingredients phellodendron extract, Banaba extract, Vanadium, and Chromium. A method of use involves taking one or two droppers (1 or 2 ml) of the solution sublingually for 30 seconds, and then swallowing.

Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed. The glycogen manager formula includes the effective ingredients phellodendron extract, Banaba extract, Vanadium, and Chromium. A method of use involves taking one or two droppers (1 or 2 ml) of the solution sublingually for 30 seconds, and then swallowing.

Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed. The glycogen manager formula includes the effective ingredients phellodendron extract, Banaba extract, Vanadium, and Chromium. A method of use involves taking one or two droppers (1 or 2 ml) of the solution sublingually for 30 seconds, and then swallowing.

The disclosure provides methods for treating estrogen receptor positive (ER.sup.+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER.sup.+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. The provided methods involve the administration of an effective amount of lasofoxifene, a pharmaceutically acceptable salt, prodrug or functional derivative thereof.

The disclosure provides methods for treating estrogen receptor positive (ER.sup.+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER.sup.+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. The provided methods involve the administration of an effective amount of lasofoxifene, a pharmaceutically acceptable salt, prodrug or functional derivative thereof.

The present invention relates to the field of medicine, particularly to novel uses of C-19 steroid compounds having an androsten-17-(OR.sub.4)-3-one structure for inhibiting angiogenesis and particularly the proliferation and/or migration of endothelial cells in the treatment of diseases involving a pathological neovascularization and/or excessive regenerative processes.

The present invention relates to the field of medicine, particularly to novel uses of C-19 steroid compounds having an androsten-17-(OR.sub.4)-3-one structure for inhibiting angiogenesis and particularly the proliferation and/or migration of endothelial cells in the treatment of diseases involving a pathological neovascularization and/or excessive regenerative processes.

The present invention relates to the field of medicine, particularly to novel uses of C-19 steroid compounds having an androsten-17-(OR.sub.4)-3-one structure for inhibiting angiogenesis and particularly the proliferation and/or migration of endothelial cells in the treatment of diseases involving a pathological neovascularization and/or excessive regenerative processes.